Quality assurance of intracellular cytokine staining assays: Analysis of multiple rounds of proficiency testing

Journal of Immunological Methods

Volumn 363, Issue 2, 2011, Pages 143-157

  Jaimes, Maria C ^a   Maecker, Holden T ^b   Yan, Ming ^a   Maino, Vernon C ^a   Hanley, Mary Beth ^a   Greer, Angela ^c   Darden, Janice M ^d   D'Souza, M Patricia ^d  

^a BD BIOSCIENCES   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Pharmaceutical Product Development   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Flow cytometry; Intracellular cytokine staining; Quality assurance

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CRYOPRESERVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITY CONTROL; STAINING;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; OBSERVER VARIATION; PHOSPHOPROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTOR-ALPHA; VESICULAR TRANSPORT PROTEINS; VIRAL MATRIX PROTEINS;

EID: 78650032431     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.08.004     Document Type: Article

References (24)

1. Betts M.R., Krowka J.F., Kepler T.B., Davidian M., Christopherson C., Kwok S., Louie L., Eron J., Sheppard H., Frelinger J.A. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res. Hum. Retroviruses 1999, 15:1219.
2. Bitmansour A.D., Douek D.C., Maino V.C., Picker L.J. Direct ex vivo analysis of human CD4(+) memory T cell activation requirements at the single clonotype level. J. Immunol. 2002, 169:1207.
3. Britten C.M., Janetzki S., Ben-Porat L., Clay T.M., Kalos M., Maecker H., Odunsi K., Pride M., Old L., Hoos A., Romero P. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol. Immunother. 2009, 58:1701.
4. Bull M., Lee D., Stucky J., Chiu Y.L., Rubin A., Horton H., McElrath M.J. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 2007, 322:57.
5. Cheng, C., Gall, J.G., Nason, M., King, C.R., Koup, R.A., Roederer, M., McElrath, M.J., Morgan, C.A., Churchyard, G., Baden, L.R., Duerr, A.C., Keefer, M.C., Graham, B.S., Nabel, G.J., 2010. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84, 630-8.
6. Cox J.H., Ferrari G., Kalams S.A., Lopaczynski W., Oden N., D'Souza M.P. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses 2005, 21:68.
7. Currier J.R., Kuta E.G., Turk E., Earhart L.B., Loomis-Price L., Janetzki S., Ferrari G., Birx D.L., Cox J.H. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 2002, 260:157.
8. De Rosa S.D., McElrath M.J. T cell responses generated by HIV vaccines in clinical trials. Curr. Opin. HIV AIDS 2008, 3:375.
9. Dunne J.M.H. Automation of cytokine flow cytometry assays. J. Assoc. Lab. Automation 2004, 9:5.
10. Ezzelle J., Rodriguez-Chavez I.R., Darden J.M., Stirewalt M., Kunwar N., Hitchcock R., Walter T., D'Souza M.P. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J. Pharm. Biomed. Anal. 2008, 46:18.
11. Goonetilleke N., Liu M.K., Salazar-Gonzalez J.F., Ferrari G., Giorgi E., Ganusov V.V., Keele B.F., Learn G.H., Turnbull E.L., Salazar M.G., Weinhold K.J., Moore S., Letvin N., Haynes B.F., Cohen M.S., Hraber P., Bhattacharya T., Borrow P., Perelson A.S., Hahn B.H., Shaw G.M., Korber B.T., McMichael A.J. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 2009, 206:1253.
12. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., Cao Y., Ho D.D., Yilma T., Caliendo A.M., Johnson R.P., Buchbinder S.P., Walker B.D. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 1996, 12:585.
13. Horton H., Thomas E.P., Stucky J.A., Frank I., Moodie Z., Huang Y., Chiu Y.L., McElrath M.J., De Rosa S.C. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J. Immunol. Methods 2007, 323:39.
14. Janetzki S., Panageas K.S., Ben-Porat L., Boyer J., Britten C.M., Clay T.M., Kalos M., Maecker H.T., Romero P., Yuan J., Kast W.M., Hoos A. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 2008, 57:303.
15. Klein M.R., van Baalen C.A., Holwerda A.M., Kerkhof Garde S.R., Bende R.J., Keet I.P., Eeftinck-Schattenkerk J.K., Osterhaus A.D., Schuitemaker H., Miedema F. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 1995, 181:1365.
16. Koup, R.A., Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M.C., Larkin, B.D., Enama, M.E., Ledgerwood, J.E., Bailer, R.T., Mascola, J.R., Nabel, G.J., Graham, B.S., 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5, e9015.
17. Maecker H.T., Dunn H.S., Suni M.A., Khatamzas E., Pitcher C.J., Bunde T., Persaud N., Trigona W., Fu T.M., Sinclair E., Bredt B.M., McCune J.M., Maino V.C., Kern F., Picker L.J. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 2001, 255:27.
18. Maecker H.T., Hassler J., Payne J.K., Summers A., Comatas K., Ghanayem M., Morse M.A., Clay T.M., Lyerly H.K., Bhatia S., Ghanekar S.A., Maino V.C., Delarosa C., Disis M.L. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 2008, 9:9.
19. Maecker H.T., Rinfret A., D'Souza P., Darden J., Roig E., Landry C., Hayes P., Birungi J., Anzala O., Garcia M., Harari A., Frank I., Baydo R., Baker M., Holbrook J., Ottinger J., Lamoreaux L., Epling C.L., Sinclair E., Suni M.A., Punt K., Calarota S., El-Bahi S., Alter G., Maila H., Kuta E., Cox J., Gray C., Altfeld M., Nougarede N., Boyer J., Tussey L., Tobery T., Bredt B., Roederer M., Koup R., Maino V.C., Weinhold K., Pantaleo G., Gilmour J., Horton H., Sekaly R.P. Standardization of cytokine flow cytometry assays. BMC Immunol. 2005, 6:13.
20. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O.D., Carter D.K., Hural J., Akondy R., Buchbinder S.P., Robertson M.N., Mehrotra D.V., Self S.G., Corey L., Shiver J.W., Casimiro D.R. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894.
21. Nomura L.E., Walker J.M., Maecker H.T. Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells. Cytometry 2000, 40:60.
22. Nomura L., Maino V.C., Maecker H.T. Standardization and optimization of multiparameter intracellular cytokine staining. Cytometry A 2008, 73:984.
23. Rinaldo C., Huang X.L., Fan Z.F., Ding M., Beltz L., Logar A., Panicali D., Mazzara G., Liebmann J., Cottrill M., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 1995, 69:5838.
24. Sarzotti-Kelsoe M., Cox J., Cleland N., Denny T., Hural J., Needham L., Ozaki D., Rodriguez-Chavez I.R., Stevens G., Stiles T., Tarragona-Fiol T., Simkins A. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med. 2009, 6:e1000067.